Product
relatlimab+nivolumab
Aliases
BMS-986213, Opdualag, Relatlimab
Name
Relatlimab
2 clinical trials
2 drugs
1 indication
Indication
MelanomaDrug
relatlimabDrug
RELAClinical trial
A Phase 3 Study of Fixed Dose Combinations of Fianlimab and Cemiplimab Versus Relatlimab and Nivolumab in Participants With Unresectable or Metastatic MelanomaStatus: Not yet recruiting, Estimated PCD: 2027-03-22
Clinical trial
A Phase 2 Randomized Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)Status: Active (not recruiting), Estimated PCD: 2024-05-28